Sobi to present new gout data at ACR Convergence 2026

Barchart · 2d ago

STOCKHOLM, Nov. 3, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that six abstracts covering pozdeutinurad (AR882), nanoencapsulated sirolimus plus pegadricase (NASP) and uncontrolled gout will be presented at ACR Convergence 2026, the American College of Rheumatology annual meeting, taking place 6–11 November 2026 in Orlando, Florida. The presentations include results from the Phase 3 REDUCE-2 study of pozdeutinurad, analyses from the DISSOLVE I/II Phase 3 trials of NASP, and real-world and patient preference research on uncontrolled gout in the United States.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.